Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Prato
Clinical trial register · Italy

Clinical Trials in Prato, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6788 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:19 UTC
6788
Studies in scope
all four open statuses
4077
Recruiting now
open to new participants
1016
Lead sponsors
across recruiting studies
Top sites
Milan 2855 Bologna 1282 Roma 1266 Naples 983 Rome 968
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Italian Sarcoma Group5 AstraZeneca4 Eli Lilly and Company3 Fondazione Sandro Pitigliani2 Meyer Children's Hospital IRCCS2 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2 ETOP IBCSG Partners Foundation2 Celcuity Inc1 Abbisko Therapeutics Co, Ltd1 GlaxoSmithKline1 K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc1 Seagen, a wholly owned subsidiary of Pfizer1 Azienda Ospedaliero-Universitaria Careggi1 TORL Biotherapeutics, LLC1 Servier Bio-Innovation LLC1 Centro Cardiopatici Toscani1 Bristol-Myers Squibb1 Corbus Pharmaceuticals Inc.1 Genmab1 Daiichi Sankyo1 Inhibrx Biosciences, Inc1 Region Örebro County1
Site location
Milan2855 Bologna1282 Roma1266 Naples983 Rome968 Florence788 Pavia573 Brescia523 Padova504 Genova490 Rozzano473 Bari451 Pisa401 Bergamo378 Meldola355 Catania340 Ancona298 Monza281 Verona281 Palermo277 Torino275 Modena259 Aviano201 Messina167 Alessandria164 Show all 490
All 490 locations
Target enrolment
to

Trials with a site in Prato

35 of 6788 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Ancona, Milan, Modena, Pisa, Prato, Rozzano, Verona
2026-09-29
Recruiting
Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
NCT07855679Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension, Right Ventricular Dysfunction, Pulmonary Embolism (PE)
Azienda Ospedaliero-Universitaria Careggi
Observational
5,000
Bagno a Ripoli, Borgo San Lorenzo, Empoli, Florence, Pescia, Pistoia, Prato, Lido di Camaiore
2026-06-19
Recruiting
Eli Lilly and Company
Phase 2
600
Genova, Milan, Misterbianco, Prato, Roma
2026-05-13
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Bologna, Florence, Milan, Naples, Pisa, Prato, Roma, Rome
2026-04-17
Recruiting
ETOP IBCSG Partners Foundation
Phase 3
390
Meldola, Milan, Novara, Pavia, Perugia, Prato, Siena, Treviso
2026-01-12
Recruiting
Genmab
Phase 3
660
Bologna, Catania, Meldola, Monza, Milan, Prato, Reggio Emilia
2025-11-28
Recruiting
Italian Sarcoma Group
Phase 2
20
Candiolo, Milan, Padova, Prato, Roma
2025-11-21
Recruiting
Eli Lilly and Company
Phase 3
1,630
Bologna, Catania, Lecce, Lucca, Milan, Modena, Naples, Prato
2025-10-22
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Naples, Bologna, Aviano, Genoa, Pontedera, Prato, Milan, Novara
2025-09-11
Recruiting
SLIT ABS: Study on Patients With Autoimmune Podocytopathy
NCT07516964Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Meyer Children's Hospital IRCCS
Not applicable
50
Bagno a Ripoli, Florence, Bologna, Genova, Parma, Pisa, Prato, Reggio Emilia
2025-06-10
Recruiting
Meyer Children's Hospital IRCCS
Observational
138
Arezzo, Bagno a Ripoli, Florence, Pisa, Pistoia, Prato, Siena
2024-12-04
Recruiting
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
DrugsTORL-1-23·Pegfilgrastim
TORL Biotherapeutics, LLC
Phase 2
230
Bari, Milan, Prato, Rome
2024-11-20
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
156
Bologna, Milan, Orbassano, Padova, Palermo, Prato, Roma
2024-07-09
Recruiting
Region Örebro County
Phase 3
495
Florence, Prato
2024-04-01
Recruiting
GlaxoSmithKline
Phase 3
864
Bolzano, Bologna, Milan, Naples, Pavia, Prato, Roma, Rozzano MI
2024-03-21
Recruiting
Daiichi Sankyo
Phase 3
250
Bari, Bologna, Genova, Milan, Misterbianco, Naples, Padova, Prato
2023-12-30
Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Observational
100
Bologna, Careggi, Rozzano, Milan, Padova, Palermo, Prato, Roma
2023-12-01
Active, closed
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 3
94
Bologna, Milan, Prato
2023-04-27
Active, closed
Celcuity Inc
Phase 3
701
Milan, Modena, Monza, Parma, Prato, Rome, Udine
2022-12-08
Recruiting
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
NCT05483374Head and Neck Cancer, Nasopharynx Cancer, Nasal Cavity and Paranasal Sinus Cancer, Salivary Gland Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Observational
13,600
Genova, Milan, Rozzano, Pavia, Prato, Roma
2022-05-31
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Naples, Genoa, Monza (MB), Catania (CT), Torrette, Trento, Livorno, Prato
2022-03-07
Recruiting
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
NCT04383119Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
DrugsTrabectedin·Gemcitabine
Italian Sarcoma Group
Phase 2
100
Bologna, Meldola, Prato, Rozzano, Aviano, Roma, Candiolo, Orbassano
2021-10-29
Active, closed
AstraZeneca
Phase 3
732
Bologna, Candiolo, Florence, Meldola, Milan, Naples, Padova, Prato
2021-10-18
Active, closed
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075Conventional Chondrosarcoma
DrugINBRX-109
Inhibrx Biosciences, Inc
Phase 2
206
Bologna, Candiolo, Milan, Palermo, Prato, Roma
2021-09-23
Recruiting
Italian Sarcoma Group
Phase 2
16
Prato, Roma, Candiolo, Bologna, Milan, Palermo
2021-09-14
Active, closed
AstraZeneca
Phase 3
506
Ancona, Bergamo, Catania, Milan, Naples, Padova, Prato
2021-06-22
Active, closed
AstraZeneca
Phase 3
893
Bologna, Florence, Misterbianco, Naples, Padova, Prato, Roma
2021-05-10
Recruiting
Italian Sarcoma Group
Observational
300
Bologna, Milan, Rozzano, Palermo, Aviano, Prato, Roma, Candiolo
2021-04-02
Recruiting
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
NCT04660435Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer
Fondazione Sandro Pitigliani
Observational
150
Prato
2020-12-01
Active, closed
Fondazione Sandro Pitigliani
Phase 2
116
Prato
2018-12-27
Recruiting
An Observational Study on Epithelioid Sarcoma
NCT03099681Epithelioid Sarcoma
Italian Sarcoma Group
Observational
100
Meldola, Milan, Rozzano, Palermo, Candiolo, Bologna, Padova, Prato
2017-08-22
Recruiting
Centro Cardiopatici Toscani
Observational
2,500
Prato
2016-12-01
Active, closed
ETOP IBCSG Partners Foundation
Not applicable
518
Prato, Carpi, Trento, Castellanza, Aviano, Biella, Bolzano, Genova
2014-12-04
Active, closed
Eli Lilly and Company
Phase 3
493
Brindisi, Cona, Genoa, Candiolo, Prato, Negrar, Bergamo, Bologna
2014-11-06
Active, closed
AstraZeneca
Phase 3
736
Aviano, Bergamo, Carpi, Genova, Prato, Reggio Emilia, Varese
2005-02-13
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-italy/city/prato

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,788 studies in total at the last sync on 13 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 35 of those studies with a site in Prato.

How many clinical trials are recruiting in Prato?

24 of the 35 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Prato), 35 studies
PhaseStudiesRecruitingShare
Phase 317948.6%
Observational8822.9%
Phase 27520%
Not applicable215.7%
Phase 2/3112.9%

Most active sponsors

Lead sponsors with the most studies (Prato)
Lead sponsorStudiesRecruiting
Italian Sarcoma Group55
AstraZeneca40
Eli Lilly and Company32
ETOP IBCSG Partners Foundation21
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano22
Fondazione Sandro Pitigliani21
Meyer Children's Hospital IRCCS22
Abbisko Therapeutics Co, Ltd10
Azienda Ospedaliero-Universitaria Careggi11
Bristol-Myers Squibb11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.